Recently, insomnia disorder has been redefined as a condition in its own right and should be managed and prioritised accordingly. Thus, insomnia patients are often overlooked. We further discuss future perspectives and key actions needed to achieve the optimal management of chronic insomnia in Europe.ĭespite the fact that sleep problems are quite common in the general population (>30%) and even more so among patients visiting primary care physicians (>50%), they are not routinely addressed in physician–patient consultations. In this article, we aim to identify these differences and compare and contrast the unmet needs with regard to disease management, physicians’ practices, and healthcare policies in western European countries. National and local differences in healthcare services lead to variable clinical care across Europe. ![]() Nevertheless, there are considerable unmet needs in the everyday clinical management of chronic insomnia which creates challenges for both treating physicians and patients. Treatment approaches include non-pharmacological as well as pharmacological options, each with specific benefits and limitations. Therefore, chronic insomnia poses a considerable burden on patients and healthcare systems. Patients with persistent insomnia are more likely to develop serious comorbidities such as cardiovascular diseases, diabetes, arterial hypertension, depression, anxiety, and cognitive functioning impairment. ![]() Healthy sleep has recently been added as one of the pillars of cardiovascular health. Furthermore, there is a reciprocal association between sleep and general health status. They also experience significant daytime consequences affecting their functioning and wellbeing, such as fatigue, concentration issues, poor social and occupational functioning, cognitive impairment, and mood disturbances. Patients with chronic insomnia experience frequent and persistent difficulties initiating or maintaining sleep despite having adequate time and conditions to sleep. Finally, suggestions are provided-with healthcare providers and healthcare policy makers in mind-for strategies to achieve the optimal clinical management.Īpproximately one in ten adults in Europe have chronic insomnia and the overall prevalence is increasing. Challenges of treating chronic insomnia in European healthcare systems, considering patients’ perspectives and preferences are presented and discussed. Old and new treatments are summarised with information on indications, contraindications, precautions, warnings, and side effects. ![]() In this article, we provide an update on the clinical management of chronic insomnia in Europe. Available evidence suggests that patients in Europe have multiple unmet needs, and actions for clearer diagnosis of chronic insomnia and effective management of this condition are long overdue. Typically, a patient with chronic insomnia (a) will usually present to a primary care physician (b) will not be offered cognitive behavioural therapy for insomnia-the recommended first-line treatment (c) will instead receive sleep hygiene recommendations and eventually pharmacotherapy to manage their long-term condition and (d) will use medications such as GABA receptor agonists for longer than the approved duration. ![]() Regional differences in practices and access to healthcare services lead to variable clinical care across Europe. One in ten adults in Europe have chronic insomnia, which is characterised by frequent and persistent difficulties initiating and/or maintaining sleep and daily functioning impairments.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |